Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
9.73 ^USD	+3.29%		+3.51%	-11.14%

06-12	Transcript : Precision BioSciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM
06-05	Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress	CI

Precision BioSciences, Inc. Appoints Sam Wadsworth and Shari Lisa Pir?, J.D. to Board of Directors

November 08, 2021 at 07:30 am

Precision BioSciences, Inc. announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy, an operating unit of Ultragenyx Pharmaceutical Inc., and Shari Lisa Pir?, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company?s Board of Directors.

Latest news about Precision BioSciences, Inc.

Transcript : Precision BioSciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM	06-12
Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress	06-05	CI
Certain Stock Options of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	05-30	CI
Certain Common Stock of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	05-30	CI
Transcript : Precision BioSciences, Inc. - Special Call	05-29
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M	05-13	MT
Precision BioSciences, Inc. announced that it has received $0.3 million in funding	05-07	CI
Guggenheim Starts Precision BioSciences With Buy Rating, $19 Price Target	04-30	MT
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	04-16	MT
Transcript : Precision BioSciences, Inc. - Special Call	04-16
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	04-16	CI
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	03-27	MT
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	03-06	CI
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	03-01	MT
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	02-20	CI
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness	02-14	CI
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.	02-11	CI
Precision BioSciences Announces 1-for-30 Reverse Stock Split; Shares Fall	02-09	MT
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	01-09	MT
TG Therapeutics, Inc. Announces Global License Agreement with Precision BioSciences, Inc. for the Development and Commercialization of Precision?s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases	01-09	CI
Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure	12-13	CI
Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases	12-04	CI

Chart Precision BioSciences, Inc.

Duration

Period

More charts

Company Profile

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Companyâs in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Precision BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.73 USD

Average target price

33 USD

Spread / Average Target

+239.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRECISION BIOSCIENCES, INC.	-11.14%	67.39M
MODERNA, INC.	+19.41%	45.51B
IQVIA HOLDINGS INC.	-8.62%	38.52B
LONZA GROUP AG	+37.83%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research